Insmed, Inc. (INSM) Dividend History

Company News

• 8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - Pipeline Innovations Expected to Add $1.8 Billion in Bronchiectasis Market Sales

  The report forecasts the bronchiectasis treatment market to reach $3.7 billion by 2033, driven by emerging pipeline agents expected to contribute an additional $1.8 billion in sales.

  GlobeNewswire Inc.

  Featured Companies: ARMP REGN
• Bronchiectasis Market to Show Positive Growth at a CAGR of 13.7% by 2034 | DelveInsight

  The bronchiectasis market is expected to grow at a CAGR of 13.7% from 2024 to 2034, driven by the launch of new treatments like Brensocatib and CMS I-neb, advancements in diagnostics, and the increasing incidence of the disease.

  GlobeNewswire Inc.

  Featured Companies: ARMP
• Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight

  The article discusses the evolving landscape of rare cardiovascular diseases, including Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy. It highlights the challenges in diagnosis and treatment, as well as the growing market size and pipeline of new therapies for these conditions.

  GlobeNewswire Inc.

  Featured Companies: ABBV CPIX GOSS JNJ KNSA LQDA MRK TENX THC UTHR
• A Russell 2000 Bull Market Could Be Coming: 1 Spectacular BlackRock ETF to Buy Hand Over Fist Before It Gets Here

  The article discusses the potential for a bull market in the Russell 2000 small-cap index, driven by factors like falling interest rates and business-friendly policies. It highlights the iShares Russell 2000 ETF as a way for investors to profit from this potential rebound.

  The Motley Fool

  Featured Companies: AAPL IWM MSFT NVDA SFM SSB
• Groundbreaking Insights Unveiled in Non-Cystic Fibrosis Bronchiectasis Pipeline Report

  The report discusses emerging therapies for non-cystic fibrosis bronchiectasis, a chronic lung condition, including Brensocatib and HSK31858, which are in advanced clinical trials and show promise in reducing inflammation and improving patient outcomes.

  GlobeNewswire Inc.

  Featured Companies: ARMP